Safety and Efficacy of Etanercept in Patients With Psoriasis
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Sichuan
-
Chengdu, Sichuan, China, 610083
- General Hospital of Chengdu Military Area Command PLA
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- has plaque psoriasis and has shown an unsatisfactory response to traditional DMARDs
- 18 to 75 years old
- has PGA of 3 or more at Day 0
- has BSA of 3% or more at Day 0
- has psoriasis severe enough to be eligible to systemic therapy
- willing to use an effective method of contraception for at least 30 days before Day 0 and until at least 1 month after the last drug administration;
- capable of giving informed consent
- with normal or non clinically significant chest X-ray within 6 months prior to Day 0
- with negative Purified Protein Derivative (PPD) or Quantiferon TB Gold test within 90 days prior to Day 0
- female patients of childbearing potential have a negative serum pregnancy test
- patient is able to start etanercept per the approved product monograph
Exclusion Criteria:
- has used topical steroids, topical tar preparations, or other anti-psoriatic preparations within the two weeks prior to Day 0 or during the study period
- has presence of erythrodermic, pustular or guttate psoriasis
- has had significant infections within the 30 days prior to Day 0
- has received investigational drugs within the four weeks prior to screening or during the study period
- has been treated with systemic anti-psoriatic drugs such as steroids, retinoids, cyclosporine, PUVA therapy or methotrexate within the four weeks prior to Day 0 or during the study period
- received systemic antibiotics within the four weeks prior to Day 0
- has been treated with ultraviolet light therapy (UVB, nbUVB) within the two weeks prior to Day 0 or during the study period
- has used infliximab within 14 days of Day 0 or during the study period
- has used other biologic agents for the treatment of psoriasis besides etanercept 8 weeks prior to Day 0 or during the study period
- has had an allergic reaction to infliximab
- has an unstable or serious medical condition as defined by the investigator or presence of any significant medical condition that might cause this study to be detrimental to the patient
- uncontrolled or severe comorbidities such as poorly controlled diabetes mellitus, NYHA class III or IV heart failure, history of myocardial infarction or cerebrovascular accident or transient ischemic attack within three months of screening visit; unstable angina pectoris
- uncontrolled hypertension, oxygen-dependent severe pulmonary disease
- has a known sero-positivity for HIV virus or history of any other immunosuppressive disease
- has active or chronic Hepatitis B or C
- has any mycobacterial disease, patient with a chest X-Ray suggestive of tuberculosis or patient taking anti-tuberculosis medication
- has a known hypersensitivity to etanercept or one of its components
- has received a live attenuated vaccine within the 12 weeks prior to Day 0 or plans to receive one during the study
- current pregnancy or lactation
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Etanercept
Patients under the treatment of 50 mg Etanercept
|
|
|
Sham-vergelijker: Control
Patients under the treatment of traditional DMARDs
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Changes from baseline of Physician's Global Assessment (PGA) at 24 weeks
Tijdsspanne: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Mean Body Surface Area (BSA)
Tijdsspanne: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
|
Mean Psoriasis Area and Severity Index (PASI)
Tijdsspanne: At 0 week, 12 weeks, 24 weeks
|
At 0 week, 12 weeks, 24 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Studie start
Primaire voltooiing (Verwacht)
Primaire voltooiing
Studie voltooiing (Verwacht)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Huidziektes
- Huidziekten, papulosquameus
- Psoriasis
- Fysiologische effecten van medicijnen
- Agenten van het perifere zenuwstelsel
- Pijnstillers
- Sensorische systeemagenten
- Ontstekingsremmers, niet-steroïde
- Pijnstillers, niet-narcotisch
- Ontstekingsremmende middelen
- Antireumatische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Gastro-intestinale middelen
- Etanercept
Andere studie-ID-nummers
Andere studie-ID-nummers
- YSP20140688
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .